




PHARMACEUTICAL 2017

Sio Gene Therapies Inc.
Rank 113 of 292





PHARMACEUTICAL 2017

Sio Gene Therapies Inc.
Rank 113 of 292



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 129%, being 126% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	282,086
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,755
Liabilities, Non-Current	0
Other Assets	323
Other Compr. Net Income	0
Other Expenses	-17
Other Liabilities	0
Other Net Income	-133,162
Other Revenues	0
Property and Equipment	89
Research and Development	76,644
Selling, General and Administrative Expense	56,518

Output Variable	Value in 1000 USD
Assets	282,498
Liabilities	15,755
Expenses	133,145
Revenues	0
Stockholders Equity	266,743
Net Income	-266,307
Comprehensive Net Income	-266,307
Economic Capital Ratio	129%